ライフサイエンスコーパス: epoprostenol

1 better risk-benefit profile than intravenous epoprostenol.

2 sion has significantly improved with CCB and epoprostenol.

3 assessment of prognosis after treatment with epoprostenol.

4 Hemodynamics improved at 12 weeks with epoprostenol.

5 n 6 of 10 (60%) of those receiving long-term epoprostenol.

6 he protocol; 4 patients transitioned back to epoprostenol.

7 Over a period of 6-14 months, epoprostenol (10-28 ng/kg/min) therapy was associated wi

8 ry hypertension was treated with intravenous epoprostenol, 23 ng/kg/min, for a 4-month period, after

9 een introduced, and may have advantages over epoprostenol administration.

10 ed monotherapy with bosentan, sildenafil, or epoprostenol and combination therapy.

11 ges in pulmonary vascular resistance for the epoprostenol and control groups were -21 percent and +9

12 es in mean pulmonary-artery pressure for the epoprostenol and control groups were -8 percent and +3 p

13 es in mean pulmonary artery pressure for the epoprostenol and conventional therapy groups were -5.0 a

14 Twenty-one patients treated with epoprostenol and no patients receiving conventional ther

15 monary hypertension with chronic intravenous epoprostenol and now report the first patient with sever

16 ension; 14 underwent acute administration of epoprostenol, and no significant side effects were noted

17 Epoprostenol appears to have sustained efficacy in this

18 tension, although predictors of outcome with epoprostenol are not well characterized.

19 nary arterial hypertension were treated with epoprostenol at our institution.

20 ucted in systemic arteries with substance P, epoprostenol, atrial natriuretic peptide, and relaxin (c

21 Because of the inconsistent availability of epoprostenol before 1995, we defined a "recent medical e

22 s treprostinil at Week 12 versus intravenous epoprostenol before transition.

23 been studied: chronic intravenously infused epoprostenol, chronic subcutaneously infused treprostini

24 Therapeutic response to epoprostenol, defined by a reduction in the pulmonary va

25 Adverse events related to the epoprostenol delivery system included sepsis, cellulitis

26 The epoprostenol dose was increased monthly to the maximum t

27 long-term effects of continuous infusion of epoprostenol (epo) therapy on survival and pulmonary art

28 The long-term effects of epoprostenol exceeded the short-term pulmonary vasodilat

29 ponders with vasodilator testing and chronic epoprostenol for nonresponders.

30 ts of the continuous intravenous infusion of epoprostenol (formerly called prostacyclin) plus convent

31 Long-term use of epoprostenol further lowered PVR (-47% +/- 12% from base

32 he quality of life were improved only in the epoprostenol group (P < 0.01).

33 Four patients in the epoprostenol group and five in the conventional therapy

34 and Dyspnea-Fatigue Ratings improved in the epoprostenol group.

35 nd fewer new digital ulcers were seen in the epoprostenol group.

36 Intravenous epoprostenol has been demonstrated to decrease pulmonary

37 Recently, continuous intravenous infusion of epoprostenol has been demonstrated to improve symptomato

38 The long-term impact that epoprostenol has made on PPH remains to be defined.

39 Epoprostenol has markedly improved the treatment of pulm

40 Older patients treated with epoprostenol have significantly shorter survival, regard

41 are treated with CCB; they are treated with epoprostenol if they become nonresponders.

42 Intravenous epoprostenol improves long-term survival in PPH.

43 Our results indicate that treatment with epoprostenol improves survival in patients with Primary

44 last 10 years, starting with the approval of epoprostenol in 1998.

45 document the efficacy of inhaled aerosolized epoprostenol in a patient with portopulmonary hypertensi

46 ut period, all patients received intravenous epoprostenol in incrementally increasing doses; toleranc

47 pulmonary hemodynamic effects of intravenous epoprostenol in patients with moderate to severe pulmona

48 We now report the use of epoprostenol in the more specific instance of PPHTN.

49 manifest favorable hemodynamic responses to epoprostenol in the short term.

50 e no data examining the effects of long-term epoprostenol in this entity.

51 Chronic epoprostenol, in conjunction with a multidisciplinary, w

52 We conclude that epoprostenol infusion is effective in improving hemodyna

53 itric oxide as acute intraoperative therapy, epoprostenol infusion represents an additional therapeut

54 The pulmonary vascular response to epoprostenol infusion serves as a deciding factor for OL

55 ion were treated with continuous intravenous epoprostenol infusions.

56 The inhaled route of delivery of epoprostenol is potential alternative for the acute ther

57 lmonary hypertension, long-term therapy with epoprostenol lowers pulmonary vascular resistance beyond

58 monary vascular resistance when treated with epoprostenol (mean, 39+/-14 percent; P=0.002).

59 Exercise capacity improved with epoprostenol (median distance walked in 6 minutes, 316 m

60 was improved in the 41 patients treated with epoprostenol (median distance walked in six minutes, 362

61 Survival for all children treated with epoprostenol (n=35) at 1, 5, and 10 years was 94%, 81%,

62 ntan with or without concomitant intravenous epoprostenol or subcutaneous treprostinil therapy.

63 Epoprostenol plus conventional therapy or conventional t

64 esthetic sophistication, and availability of epoprostenol, PPHTN is no longer considered an absolute

65 rapy, the continuous intravenous infusion of epoprostenol produced symptomatic and hemodynamic improv

66 matic patients, treatment with prostacyclin (epoprostenol) produced improvements in hemodynamics, qua

67 With current therapies such as epoprostenol, progression of disease is slowed, but not

68 e., for more than one year) with intravenous epoprostenol (prostacyclin) in patients with advanced pr

69 s "portopulmonary hypertension." Intravenous epoprostenol (prostacyclin) is a potent pulmonary and sy

70 during acute testing, continuous intravenous epoprostenol (prostacyclin, PGI2) improves haemodynamics

71 Ten patients received continuous epoprostenol (range, 8 days-30 months).

72 its delivery system, continuous intravenous epoprostenol remains the most efficacious treatment curr

73 Continuous intravenous administration of epoprostenol remains the treatment of choice in WHO func

74 e progression; i.e., death, transplantation, epoprostenol rescue, or >25% decrease in peak oxygen con

75 Acute infusion of epoprostenol resulted in a significant (p < 0.05) decrea

76 ere portopulmonary hypertension, intravenous epoprostenol resulted in a significant improvement (both

77 The complexity of epoprostenol therapy (chronic indwelling catheters, reco

78 Observed survival with epoprostenol therapy at 1, 2, and 3 years was 87.8%, 76.

79 Chronic intravenous epoprostenol therapy has had a substantial impact on the

80 Continuous epoprostenol therapy improves exercise capacity and card

81 Side effects of epoprostenol therapy included jaw pain, nausea, and anor

82 Epoprostenol therapy was initiated and the rate of infus

83 ata suggest that transition from intravenous epoprostenol to intravenous treprostinil is safe and eff

84 n label study were switched from intravenous epoprostenol to intravenous treprostinil over 24 to 48 h

85 Hemodynamics improved at 12 weeks in the epoprostenol-treated patients.

86 We analyzed the effects of long-term epoprostenol treatment to determine features associated

87 Long-term epoprostenol was generally well tolerated and provides a

88 en from the total 77 patient cohort for whom epoprostenol was recommended but was unavailable.

89 Intravenous epoprostenol was the first Food and Drug Administration-

90 Effects of long-term infusion of epoprostenol were also evaluated.

91 patients diagnosed with PPH and treated with epoprostenol were followed for a mean of 36.3 months (me

92 = 27), all patients treated with intravenous epoprostenol were weaned off post-LT, and endothelin rec

93 onary hypertension successfully treated with epoprostenol who subsequently underwent successful liver

94 continues to do well, and at 3 months is off epoprostenol with near normal pulmonary artery pressures